MGC018
Phase 2Small molecule
MGC018 is one of 44 small molecule programs targeting Lung Cancer. It is currently in Phase 2.
2
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
686 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Tecentriq
RochePreclinical
Libtayo
RegeneronPreclinical
Vizimpro
PfizerPreclinical
Talzenna
PfizerPreclinical
Folvite
Eli LillyPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
MGC018
GGeorgetown University
Phase 2
Paclitaxel and Carboplatin
Bristol-Myers SquibbPreclinical
Rilotumumab
AmgenPreclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MGC018. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- GGeorgetown University